Skip to content
Screener

Syndax Pharmaceuticals SNDX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Biogen logo
BiogenBIIB
$32.09B+13.3%
Incyte logo
IncyteINCY
$7.87B+35.2%
SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.SLS
$114.18M+227%
Kura Oncology logo
Kura OncologyKURA
$652.55M-12.3%
AbbVie logo
AbbVieABBV
$136.46B+0.2%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$349.3M+62.1%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.76B+58.9%
Enterprise value$1.98B+48.9%
P/S8.1×-6.1×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-197154
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value, 200,000,000 shares authorized; 88,543,881 and 87,405,979 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively99
Additional paid-in capital1,590,8551,570,749
Accumulated other comprehensive gain11452
Accumulated deficit(1,549,253)(1,506,580)
Total stockholders’ equity41,62264,630
Total liabilities and stockholders’ equity$472,668$529,706

Item 1: Financial Statements

FAQ

What is Syndax Pharmaceuticals's total liabilities & equity?
Syndax Pharmaceuticals (SNDX) reported total liabilities & equity of $472.67M in Q1 2026.
How has Syndax Pharmaceuticals's total liabilities & equity changed year-over-year?
Syndax Pharmaceuticals's total liabilities & equity decreased by 26.2% year-over-year, from $640.71M to $472.67M.
What is the long-term trend for Syndax Pharmaceuticals's total liabilities & equity?
Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total liabilities & equity has grown at a 12.0% compound annual growth rate (CAGR), from $300.61M to $529.71M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Syndax Pharmaceuticals's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude